FDA approves Exdensur, twice yearly biologic for severe asthma

The Food and Drug Administration granted approval for Exdensur, a long acting monoclonal antibody developed by GlaxoSmithKline, as an add on maintenance therapy for severe asthma characterized by an eosinophilic phenotype in adults and pediatric patients aged 12 years and older. GSK issued a company news release announcing the decision on December 16, 2025, and media coverage followed through December 22, 2025.

Exdensur, listed generically as depemokimab u laa and also referenced as depemokimab or GSK3511294 in clinical registries, is administered as two injections per year. The product is described as an anti interleukin 5 therapy with enhanced binding affinity for interleukin 5, a pathway implicated in eosinophil driven inflammation that contributes to severe asthma exacerbations.

The approval was supported by the phase 3 SWIFT clinical program, which included at least two pivotal trials known as SWIFT 1 and SWIFT 2. More than 760 participants were enrolled across the trials and the core studies ran for 52 weeks. In SWIFT 1, Exdensur plus standard of care reduced annualized asthma exacerbation rates by 58 percent compared with placebo plus standard of care. In SWIFT 2 the reduction was 48 percent. Published trial figures reported absolute annualized exacerbation rates of 0.46 versus 1.11 in one study and 0.56 versus 1.08 in the other for Exdensur and placebo arms respectively. A peer reviewed article in the New England Journal of Medicine in 2024 detailed twice yearly depemokimab in severe asthma with an eosinophilic phenotype and is cited in regulatory summaries.

Safety signals in the SWIFT program were reported as broadly similar between Exdensur and placebo groups over the trial period, and trial summaries released with the approval stated that no serious adverse events were attributed to the drug. Regulators will continue to monitor post approval safety in broader clinical use.

The approval positions Exdensur as the first asthma biologic approved for twice yearly dosing, a property analysts and clinicians say could improve adherence and reduce the clinical burden of frequent injections. For patients who struggle with regular clinic visits or device management, fewer injections could translate into fewer exacerbations, less emergency care, and lower health system utilization if efficacy in the real world mirrors trial results.

Yet the potential public health gains are tempered by equity concerns. Specialty biologics often carry high price tags and require prior authorization and specialty pharmacy distribution, barriers that disproportionately affect low income and rural patients. Insurers will determine coverage policies and patient cost sharing, shaping who benefits first. Clinics serving underserved communities may lack the infrastructure for specialty injection administration and follow up, creating further disparities.

Internationally, the European regulator has advanced depemokimab toward approval for additional indications including chronic rhinosinusitis with nasal polyps, but the FDA approval is limited to severe eosinophilic asthma in patients aged 12 and older. As Exdensur moves into wider use, clinicians and policymakers will need to balance promising clinical benefits against access challenges to ensure equitable delivery of this new twice yearly option.